Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Polyethylene Wear Particle Analysis of THA

NCT06432543 · tracked via the Priya Life Science Japan tracker
Phase
Observational
Started
2024-06-01
Last updated
2025-01-20

Condition(s) studied

Wear of Articular Bearing Surface of Prosthetic JointHip Arthropathy

Investigational drug(s) / intervention(s)

polyethylene

polyethylene: No intervention as this is an observational study

Study summary

Purpose of research The purpose of this study was to demonstrate that polyethylene (Vitamin E-containing polyethylene), a newly introduced biomaterial for tibial inserts in hip replacement surgery and widely used clinically, but whose mid- to long-term clinical results are still unknown, is superior to conventional polyethylene in vivo. The aim of this project is to conduct an international multi-center joint research study to determine whether polyethylene wear debris production can be reduced in the future, using an in vivo polyethylene wear debris analysis method that the investigators developed as a method that can provide early feedback.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients undergoing revision hip arthroplasty within the study period 2. Patients over 20 years old 3. Patients who have received a sufficient explanation, have sufficient understanding, and have given their free written consent. 4. Patients who have passed 2 years or more since their first total hip arthroplasty Exclusion Criteria: 1\. Patients who are judged to be unsuitable as research subjects by the research physician

Primary outcome measure(s)

  • Number of polyethylene wear particles — When tissue sample was collected during THA revision surgery
    counts / g (tissue sample)
  • Equivalent circle diameter of polyethylene wear particles — When tissue sample was collected during THA revision surgery
    equivalent circle diameter \[㎛\]
  • Aspect ratio of polyethylene wear particles — When tissue sample was collected during THA revision surgery
    aspect ratio
  • Roundness of polyethylene wear particles — When tissue sample was collected during THA revision surgery
    roundness

Trial sites (2)

FacilityCityRegionStatus
Mayo Clinic Rochester Minnesota Not Yet Recruiting
Osaka Metropolitan University Osaka Japan Recruiting

More Osaka Metropolitan University trials in Japan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06432543 on ClinicalTrials.gov ↗ ← All trials in Japan